ZHAOKE OPHTHALMOLOGY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.48 HKD | -2.63% |
|
-6.92% | -62.53% |
| Apr. 29 | Zhaoke Ophthalmology Shrinks Loss in 2023 | MT |
| Apr. 08 | Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,517 | 1,451 | 1,961 | 749.3 | - | - |
| Enterprise Value (EV) 1 | 417.5 | -237.3 | 1,961 | -311.3 | 65.15 | 318.1 |
| P/E ratio | -0.9 x | -3.56 x | -5.06 x | - | - | - |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 105 x | 25.7 x | 4.98 x | 1.77 x |
| EV / Revenue | - | - | 105 x | -10.7 x | 0.43 x | 0.75 x |
| EV / EBITDA | -1.23 x | 0.64 x | -4.82 x | 0.75 x | -0.17 x | -1.41 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 1.01 x | 0.62 x | - | - | - | - |
| Nbr of stocks (in thousands) | 541,947 | 543,844 | 546,139 | 546,139 | - | - |
| Reference price 2 | 4.644 | 2.667 | 3.590 | 1.372 | 1.372 | 1.372 |
| Announcement Date | 3/23/22 | 3/27/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 18.75 | 29.14 | 150.4 | 422.2 |
| EBITDA 1 | - | -338.5 | -369.1 | -406.4 | -413.9 | -377.7 | -226.1 |
| EBIT 1 | - | -364.3 | -404.2 | -455.1 | -442.9 | -404.4 | -251 |
| Operating Margin | - | - | - | -2,427.18% | -1,519.72% | -268.91% | -59.46% |
| Earnings before Tax (EBT) | - | - | -407.3 | - | - | - | - |
| Net income | -727 | -2,130 | -407.3 | - | - | - | - |
| Net margin | - | - | - | - | - | - | - |
| EPS | - | -5.160 | -0.7500 | -0.7100 | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 4/16/21 | 3/23/22 | 3/27/23 | 3/27/24 | - | - | - |
1CNY in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 11.3 | 7.446 | 11.66 | 17.48 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -122.4 | -241.9 | -137.6 | -266.6 | -214.5 | -240.6 | -207.8 | -235 |
| Operating Margin | - | - | - | - | -1,897.92% | -3,230.66% | -1,782.91% | -1,344.27% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/18/21 | 3/23/22 | 8/24/22 | 3/27/23 | 8/23/23 | 3/27/24 | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 2,100 | 1,688 | - | 1,061 | 684 | 431 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -243% | -16.8% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | -15.7% | - | - | - | - |
| Assets | - | - | 2,588 | - | - | - | - |
| Book Value Per Share | - | 4.600 | 4.320 | - | - | - | - |
| Cash Flow per Share | - | -0.5900 | -0.6100 | - | - | - | - |
| Capex | - | 50.4 | 54.9 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 4/16/21 | 3/23/22 | 3/27/23 | 3/27/24 | - | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.372
CNY
Average target price
7.1
CNY
Spread / Average Target
+417.55%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -62.53% | 103M | |
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B |
- Stock Market
- Equities
- 6622 Stock
- Financials Zhaoke Ophthalmology Limited
